Related Experiment Videos
Case study. Risperidone-Induced neuroleptic malignant syndrome in an adolescent.
1Department of Psychiatry and Behavioral Science, The Children's National Medical Center, Washington, DC 20010, USA. arobb@cnmc.org
Journal of Child and Adolescent Psychopharmacology
|February 24, 2001
Summary
Neuroleptic malignant syndrome (NMS), a severe reaction to antipsychotic drugs, can occur with newer medications. This case highlights NMS in a young patient treated with risperidone, questioning the safety of atypical neuroleptics.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Neuroleptic malignant syndrome (NMS) is a critical, life-threatening condition associated with antipsychotic medication.
- Historically linked to high-potency typical neuroleptics, NMS is increasingly reported with atypical agents.
Observation:
- This report details a case of NMS in the youngest patient documented to date.
- The patient developed NMS following treatment with risperidone, an atypical neuroleptic.
Findings:
- The case demonstrates that atypical neuroleptics, such as risperidone, can induce NMS.
- This finding challenges previous assumptions about the safety profile of newer antipsychotic medications.
Implications:
- The occurrence of NMS in a young patient underscores the need to re-evaluate the safety of atypical neuroleptics.
- Clinical vigilance and prompt recognition are crucial for managing NMS, regardless of the neuroleptic agent used.